Table 4.
Summary of publications assessing renal replacement therapy in patients with cancer admitted into ICU.
| Reference | Population | N | RRT | Mortality | Prognostic factors for hospital mortality |
|---|---|---|---|---|---|
| Mixed population (solid and hematological tumors, including bone marrow transplantation) | |||||
| Berghmans et al. (15) | Solid: 50% | 32 | CVVHDF | ICU: 50% | Number of organ failure |
| Hemato: 50% | Hospital: 53% | ||||
| BMT: 28% | |||||
| Salahudeen et al. (5) | Solid: 38% | 199 | C-SLED | Day 30: 65% | SOFA score, pH, mean blood pressure |
| Hemato: 62% | |||||
| BMT: 18% | |||||
| Mixed population (solid and hematological tumors, excluding bone marrow transplantation) | |||||
| Maccariello et al. (13) | Solid: 73% | 118 | IRRT daily conventional | ICU: 70% | Number of organ failure |
| Hemato: 27% | IRRT daily extended | Hospital: 78% | |||
| CRRT | |||||
| Darmon et al. (7) | Solid: 7% | 94 | CRRT | ICU: 43.6% | LOD score, late RRT (>24 h after ICU admission) |
| Hemato: 78% | IRRT | Hospital: 51.1% | |||
| Other: 15% | 6 months: 65.4% | ||||
| Soares et al. (14) | Solid: 75% | 98 | IRRT conventional | Hospital: 64–86% | – |
| Hemato: 25% | IRRT extended | ||||
| CRRT | |||||
| Hematological tumors | |||||
| Letourneau et al. (12) | BMT: 100% | 14 | CVVHDF | – | – |
| IRRT | |||||
| Lanore et al. (11) | BMT: 11% | 43 | ICU: 72% | ARF secondary to sepsis, SAPS score, mechanical ventilation support | |
| Benoit et al. (9) | BMT: 22.4% | 50 | IRRT | ICU: 79.6% | – |
| CRRT | Hospital: 83.7% | ||||
| 6 months: 86% | |||||
Cancer series found by PubMed search using the MESH terms “Acute kidney injury” and “Intensive care.”
RRT, renal replacement therapy; CVVHDF, continuous venovenous hemodiafiltration; ICU, intensive care unit; C-SLED, sustained low efficiency dialysis in the continuous mode; CRRT, continuous renal replacement therapy; IRRT, intermittent renal replacement therapy; BMT, bone marrow transplantation; ARF, acute renal failure.